Increase	increase	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	O	OTHERS	I
disability	disability	O	O	OTHERS	I
after	after	O	O	O	O
fluoxetine	fluoxetine	CHEMICALS	O	OTHERS	I
medication	medication	O	O	O	O
.	.	O	O	O	O

Depression	depression	O	DISEASE	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
clinical	clinical	O	O	O	O
feature	feature	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
the	the	O	O	O	O
increased	increased	O	O	O	O
amount	amount	O	O	O	O
of	of	O	O	O	O
motor	motor	O	DISEASE	OTHERS	I
disability	disability	O	DISEASE	OTHERS	I
in	in	O	O	O	O
four	four	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
idiopathic	idiopathic	O	DISEASE	OTHERS	I
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
after	after	O	O	O	O
exposure	exposure	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
antidepressant	antidepressant	CHEMICALS	O	OTHERS	I
fluoxetine	fluoxetine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
possibility	possibility	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
clinically	clinically	O	O	O	O
relevant	relevant	O	O	O	O
dopamine-antagonistic	dopamine-antagonistic	O	O	O	O
capacity	capacity	O	O	O	O
of	of	O	O	O	O
fluoxetine	fluoxetine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
must	must	O	O	O	O
be	be	O	O	O	O
considered	considered	O	O	O	O
.	.	O	O	O	O

